Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis

Full text
Author(s):
Alcantara, Laura M. [1] ; Ferreira, Thalita C. S. [1] ; Gadelha, Fernanda R. [1] ; Miguel, Danilo C. [1]
Total Authors: 4
Affiliation:
[1] Univ Campinas UNICAMP, Biol Inst, Campinas, SP - Brazil
Total Affiliations: 1
Document type: Review article
Source: INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE; v. 8, n. 3, p. 430-439, DEC 2018.
Web of Science Citations: 14
Abstract

Tritryps diseases are devastating parasitic neglected infections caused by Leishmania spp., Trypanosoma cruzi and Trypanosoma brucei subspecies. Together, these parasites affect more than 30 million people worldwide and cause high mortality and morbidity. Leishmaniasis comprises a complex group of diseases with clinical manifestation ranging from cutaneous lesions to systemic visceral damage. Antimonials, the first-choice drugs used to treat leishmaniasis, lead to high toxicity and carry significant contraindications limiting its use. Drug-resistant parasite strains are also a matter for increasing concern, especially in areas with very limited resources. The current scenario calls for novel and/or improvement of existing therapeutics as key research priorities in the field. Although several studies have shown advances in drug discovery towards leishmaniasis in recent years, key knowledge gaps in drug discovery pipelines still need to be addressed. In this review we discuss not only scientific and non-scientific bottlenecks in drug development, but also the central role of public-private partnerships for a successful campaign for novel treatment options against this devastating disease. (AU)

FAPESP's process: 15/24595-9 - Correlation between the biochemical parameters of Trypanosoma cruzi isolates from Chagas disease patients with different clinical forms of the disease and the pathogenesis of the disease
Grantee:Fernanda Ramos Gadelha
Support Opportunities: Regular Research Grants
FAPESP's process: 14/21129-4 - The role of fatty acid-binding proteins in the macrophage infection by Leishmania: a potential target for new drugs against leishmaniasis
Grantee:Danilo Ciccone Miguel
Support Opportunities: Research Grants - Young Investigators Grants
FAPESP's process: 15/10436-6 - Discovery of new compounds for cutaneous and mucocutaneous leishmaniasis treatment from high content screening
Grantee:Thalita Camelo da Silva Ferreira
Support Opportunities: Scholarships in Brazil - Doctorate (Direct)